Myasthenia gravis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Hardik Patel (talk | contribs) (Created page with "__NOTOC__ {{Myasthenia gravis}} {{CMG}} ==Epidemiology and Demographics== Myasthenia gravis occurs in all ethnic groups and both genders. It most commonly affects women under...") |
(→Race) |
||
| (10 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | == Overview == | ||
Myasthenia gravis | The [[incidence]] of Myasthenia gravis is approximately 7-23 new cases per year. The [[prevalence]] of Myasthenia gravis is approximately 70-320 per million and increasing since 20<sup>th</sup> century. The [[age of onset]] in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is [[female]] predominant and the late type (after age of 60) is [[male]] predominant. Between the age of 50-60 there is no significant different between [[male]] and [[female]]. Some studies demonstrated that the [[incidence]], [[prevalence]] and the severity of this disease is higher in African/Americans. | ||
==Incidence== | |||
The [[incidence]] of Myasthenia gravis is approximately 7-23 new cases per year.<ref name="pmid20565885">{{cite journal |vauthors=Carr AS, Cardwell CR, McCarron PO, McConville J |title=A systematic review of population based epidemiological studies in Myasthenia Gravis |journal=BMC Neurol |volume=10 |issue= |pages=46 |date=June 2010 |pmid=20565885 |pmc=2905354 |doi=10.1186/1471-2377-10-46 |url=}}</ref><ref name="pmid22581533">{{cite journal |vauthors=Heldal AT, Eide GE, Gilhus NE, Romi F |title=Geographical distribution of a seropositive myasthenia gravis population |journal=Muscle Nerve |volume=45 |issue=6 |pages=815–9 |date=June 2012 |pmid=22581533 |doi=10.1002/mus.23271 |url=}}</ref><ref name="pmid25060190">{{cite journal |vauthors=Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM |title=Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa |journal=Muscle Nerve |volume=51 |issue=4 |pages=533–7 |date=April 2015 |pmid=25060190 |doi=10.1002/mus.24348 |url=}}</ref><ref name="pmid26573434">{{cite journal |vauthors=Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K |title=Epidemiology of myasthenia gravis in Ontario, Canada |journal=Neuromuscul. Disord. |volume=26 |issue=1 |pages=41–6 |date=January 2016 |pmid=26573434 |doi=10.1016/j.nmd.2015.10.009 |url=}}</ref> | |||
== Prevalence == | |||
The [[prevalence]] of Myasthenia gravis is approximately 70-320 per million and increasing since 20<sup>th</sup> century.<ref name="pmid20565885">{{cite journal |vauthors=Carr AS, Cardwell CR, McCarron PO, McConville J |title=A systematic review of population based epidemiological studies in Myasthenia Gravis |journal=BMC Neurol |volume=10 |issue= |pages=46 |date=June 2010 |pmid=20565885 |pmc=2905354 |doi=10.1186/1471-2377-10-46 |url=}}</ref><ref name="pmid22581533">{{cite journal |vauthors=Heldal AT, Eide GE, Gilhus NE, Romi F |title=Geographical distribution of a seropositive myasthenia gravis population |journal=Muscle Nerve |volume=45 |issue=6 |pages=815–9 |date=June 2012 |pmid=22581533 |doi=10.1002/mus.23271 |url=}}</ref><ref name="pmid26573434">{{cite journal |vauthors=Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K |title=Epidemiology of myasthenia gravis in Ontario, Canada |journal=Neuromuscul. Disord. |volume=26 |issue=1 |pages=41–6 |date=January 2016 |pmid=26573434 |doi=10.1016/j.nmd.2015.10.009 |url=}}</ref><ref name="pmid26851892">{{cite journal |vauthors=Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H, Silveira F, Nadais G, Morais H, Martins J, Branco MC, Veiga A, Silva RS, Ferreira A, Sousa F, Freijo M, Matos I, André R, Negrão L, Fraga C, Santos M, Sampaio M, Lopes C, Leite MI, Gonçalves G |title=Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases |journal=Muscle Nerve |volume=54 |issue=3 |pages=413–21 |date=September 2016 |pmid=26851892 |doi=10.1002/mus.25068 |url=}}</ref> | |||
== Age and Gender == | |||
The [[age of onset]] in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is [[female]] predominant and the late type (after age of 60) is [[male]] predominant. Between the age of 50-60 there is no significant different between [[male]] and [[female]].<ref name="pmid23893883">{{cite journal |vauthors=Alkhawajah NM, Oger J |title=Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing |journal=Muscle Nerve |volume=48 |issue=5 |pages=705–10 |date=November 2013 |pmid=23893883 |doi=10.1002/mus.23964 |url=}}</ref> | |||
== Race == | |||
Some studies demonstrated that the [[incidence]], [[prevalence]] and the severity of this disease is higher in African/Americans.<ref name="pmid1407568">{{cite journal |vauthors=Phillips LH, Torner JC, Anderson MS, Cox GM |title=The epidemiology of myasthenia gravis in central and western Virginia |journal=Neurology |volume=42 |issue=10 |pages=1888–93 |date=October 1992 |pmid=1407568 |doi= |url=}}</ref><ref name="pmid19127534">{{cite journal |vauthors=Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, Claussen GC |title=Racial differences in myasthenia gravis in Alabama |journal=Muscle Nerve |volume=39 |issue=3 |pages=328–32 |date=March 2009 |pmid=19127534 |pmc=2814330 |doi=10.1002/mus.21191 |url=}}</ref> | |||
The | ==Region== | ||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
==References== | ==References== | ||
| Line 27: | Line 27: | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Rheumatology]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 14:24, 15 August 2019
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis epidemiology and demographics |
|
Risk calculators and risk factors for Myasthenia gravis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The incidence of Myasthenia gravis is approximately 7-23 new cases per year. The prevalence of Myasthenia gravis is approximately 70-320 per million and increasing since 20th century. The age of onset in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is female predominant and the late type (after age of 60) is male predominant. Between the age of 50-60 there is no significant different between male and female. Some studies demonstrated that the incidence, prevalence and the severity of this disease is higher in African/Americans.
Incidence
The incidence of Myasthenia gravis is approximately 7-23 new cases per year.[1][2][3][4]
Prevalence
The prevalence of Myasthenia gravis is approximately 70-320 per million and increasing since 20th century.[1][2][4][5]
Age and Gender
The age of onset in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is female predominant and the late type (after age of 60) is male predominant. Between the age of 50-60 there is no significant different between male and female.[6]
Race
Some studies demonstrated that the incidence, prevalence and the severity of this disease is higher in African/Americans.[7][8]
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
References
- ↑ 1.0 1.1 Carr AS, Cardwell CR, McCarron PO, McConville J (June 2010). "A systematic review of population based epidemiological studies in Myasthenia Gravis". BMC Neurol. 10: 46. doi:10.1186/1471-2377-10-46. PMC 2905354. PMID 20565885.
- ↑ 2.0 2.1 Heldal AT, Eide GE, Gilhus NE, Romi F (June 2012). "Geographical distribution of a seropositive myasthenia gravis population". Muscle Nerve. 45 (6): 815–9. doi:10.1002/mus.23271. PMID 22581533.
- ↑ Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM (April 2015). "Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa". Muscle Nerve. 51 (4): 533–7. doi:10.1002/mus.24348. PMID 25060190.
- ↑ 4.0 4.1 Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K (January 2016). "Epidemiology of myasthenia gravis in Ontario, Canada". Neuromuscul. Disord. 26 (1): 41–6. doi:10.1016/j.nmd.2015.10.009. PMID 26573434.
- ↑ Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H, Silveira F, Nadais G, Morais H, Martins J, Branco MC, Veiga A, Silva RS, Ferreira A, Sousa F, Freijo M, Matos I, André R, Negrão L, Fraga C, Santos M, Sampaio M, Lopes C, Leite MI, Gonçalves G (September 2016). "Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases". Muscle Nerve. 54 (3): 413–21. doi:10.1002/mus.25068. PMID 26851892.
- ↑ Alkhawajah NM, Oger J (November 2013). "Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing". Muscle Nerve. 48 (5): 705–10. doi:10.1002/mus.23964. PMID 23893883.
- ↑ Phillips LH, Torner JC, Anderson MS, Cox GM (October 1992). "The epidemiology of myasthenia gravis in central and western Virginia". Neurology. 42 (10): 1888–93. PMID 1407568.
- ↑ Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, Claussen GC (March 2009). "Racial differences in myasthenia gravis in Alabama". Muscle Nerve. 39 (3): 328–32. doi:10.1002/mus.21191. PMC 2814330. PMID 19127534.